| ID Source | ID |
|---|---|
| PubMed CID | 25110406 |
| CHEMBL ID | 3922179 |
| CHEBI ID | 188539 |
| SCHEMBL ID | 1413272 |
| MeSH ID | M0526798 |
| Synonym |
|---|
| SR-03000000521-1 |
| cym-5442 |
| 1094042-01-9 |
| gtpl2928 |
| 2-({4-[5-(3,4-diethoxyphenyl)-1,2,4-oxadiazol-3-yl]-2,3-dihydro-1h-inden-1-yl}amino)ethan-1-ol |
| CHEBI:188539 |
| cym5442 |
| 2-[[4-[5-(3,4-diethoxyphenyl)-1,2,4-oxadiazol-3-yl]-2,3-dihydro-1h-inden-1-yl]amino]ethanol |
| 2-((4-(5-(3,4-diethoxyphenyl)-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1h-inden-1-yl)amino)ethanol |
| SCHEMBL1413272 |
| AC-35245 |
| 2-((4-(5-(3,4-diethoxyphenyl)-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1h-inden-1-yl)amino)ethan-1-ol |
| DTXSID70648731 |
| cym-5442, >=98% (hplc) |
| cym 5442 |
| EX-A903 |
| AKOS027250728 |
| mfcd12912402 |
| NCGC00370878-01 |
| CHEMBL3922179 |
| BCP16797 |
| cym-5442;cym 5442 |
| Q27076958 |
| AS-16780 |
| 2-(4-(5-(3,4-diethoxyphenyl)-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1h-inden-1-ylamino)ethanolhydrochloride |
| us10544136, compound 236 |
| bdbm427452 |
| 2-({4-[5-(3,4-diethoxyphenyl)-1,2,4-oxadiazol-3-yl]-2,3-dihydro-1h-inden-1-yl}amino)ethanol hydrochloride |
| A901194 |
| 2-(4-(5-(3,4-diethoxyphenyl)-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1h-inden-1-yl amino) ethanol;cym-5442 |
| CS-0002981 |
| HY-10968 |
| N11214 |
| Excerpt | Reference | Relevance |
|---|---|---|
| "The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs." | ( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019) | 0.51 |
| Class | Description |
|---|---|
| oxadiazole | |
| ring assembly | Two or more cyclic systems (single rings or fused systems) which are directly joined to each other by double or single bonds are named ring assemblies when the number of such direct ring junctions is one less than the number of cyclic systems involved. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Sphingosine 1-phosphate receptor 2 | Homo sapiens (human) | EC50 (µMol) | 1.0000 | 0.0007 | 0.3651 | 2.8530 | AID1339920 |
| Sphingosine 1-phosphate receptor 4 | Homo sapiens (human) | EC50 (µMol) | 3.2500 | 0.0001 | 0.2626 | 3.2500 | AID1339922 |
| Sphingosine 1-phosphate receptor 1 | Homo sapiens (human) | EC50 (µMol) | 0.0029 | 0.0000 | 0.1759 | 7.8700 | AID1339916 |
| Sphingosine 1-phosphate receptor 3 | Homo sapiens (human) | EC50 (µMol) | 4.3000 | 0.0001 | 0.3092 | 5.0000 | AID1339921 |
| Sphingosine 1-phosphate receptor 5 | Homo sapiens (human) | EC50 (µMol) | 0.1359 | 0.0002 | 0.1365 | 3.1623 | AID1339923 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1532413 | Immunosuppressive activity in ip dosed C57BL6 mouse assessed as decrease in B220+ B lymphocyte count after 5 hrs by FACS analysis | 2018 | Bioorganic & medicinal chemistry letters, 12-15, Volume: 28, Issue:23-24 | An update on sphingosine-1-phosphate receptor 1 modulators. |
| AID1532417 | Immunosuppressive activity in ip dosed C57BL6 mouse assessed as decrease in CD8+ T lymphocyte count after 5 hrs by FACS analysis | 2018 | Bioorganic & medicinal chemistry letters, 12-15, Volume: 28, Issue:23-24 | An update on sphingosine-1-phosphate receptor 1 modulators. |
| AID1532412 | Immunosuppressive activity in C57BL6 mouse assessed as decrease in B220+ B lymphocyte count at 10 mg/kg, ip after 5 hrs by FACS analysis relative to control | 2018 | Bioorganic & medicinal chemistry letters, 12-15, Volume: 28, Issue:23-24 | An update on sphingosine-1-phosphate receptor 1 modulators. |
| AID1532418 | Selectivity for S1P1 (unknown origin) over S1P5 (unknown origin) | 2018 | Bioorganic & medicinal chemistry letters, 12-15, Volume: 28, Issue:23-24 | An update on sphingosine-1-phosphate receptor 1 modulators. |
| AID1532416 | Immunosuppressive activity in C57BL6 mouse assessed as decrease in CD8+ T lymphocyte count at 10 mg/kg, ip after 5 hrs by FACS analysis relative to control | 2018 | Bioorganic & medicinal chemistry letters, 12-15, Volume: 28, Issue:23-24 | An update on sphingosine-1-phosphate receptor 1 modulators. |
| AID1532414 | Immunosuppressive activity in C57BL6 mouse assessed as decrease in CD4+ T lymphocyte count at 10 mg/kg, ip after 5 hrs by FACS analysis relative to control | 2018 | Bioorganic & medicinal chemistry letters, 12-15, Volume: 28, Issue:23-24 | An update on sphingosine-1-phosphate receptor 1 modulators. |
| AID1532415 | Immunosuppressive activity in ip dosed C57BL6 mouse assessed as decrease in CD4+ T lymphocyte count after 5 hrs by FACS analysis | 2018 | Bioorganic & medicinal chemistry letters, 12-15, Volume: 28, Issue:23-24 | An update on sphingosine-1-phosphate receptor 1 modulators. |
| AID1346987 | P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1347160 | Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1296008 | Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening | 2020 | SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1 | Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening. |
| AID1347159 | Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1346986 | P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1346170 | Human S1P1 receptor (Lysophospholipid (S1P) receptors) | 2008 | Molecular pharmacology, Nov, Volume: 74, Issue:5 | Full pharmacological efficacy of a novel S1P1 agonist that does not require S1P-like headgroup interactions. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 2 (40.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (22.58) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 1 (20.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 4 (80.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||